Incyte Corporation vs Newmont Corporation — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Newmont Corporation trades at $92.41 (market cap $95.23B). The key difference: Newmont Corporation is far larger — about 4.1× Incyte Corporation's market cap, and Newmont Corporation pays a 1.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NEM | |
|---|---|---|
Market Cap | $23.11B | $95.23B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $131.95 |
52-Week Low | $67.38 | $59.86 |
Enterprise Value | $19.13B | $91.98B |
Dividend Yield | — | 1.17% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →